Launch — Access limited to 250 Members to ensure personalized follow-up quality.

Holotranscobalamin (Active B12)

Holo-TC · HoloTC · B12 active · Vitamine B12 active · Holo-transcobalamine · Active cobalamin

Vitamins & Methylation

Tracking holo-TC over time illuminates a central axis of longevity: the methylation cycle. This cycle underpins DNA synthesis, neurotransmitter production, and cognitive health. The CAIDE cohort (Hooshmand 2010) documented that higher baseline holo-TC associates with a more favorable cognitive trajectory over the years. This measurement anchors the follow-up of B12 biological capital within a longitudinal prevention perspective.

Last updated: May 10, 2026

Physiological Role

Holotranscobalamin, or Holo-TC, refers to vitamin B12 bound to transcobalamin II, its active transport protein. Only this complex is recognized by cellular receptors and internalized into tissues. Other circulating forms of B12 remain metabolically inactive.

Once inside the cell, active B12 drives two major enzymatic pathways. It serves as a cofactor for methionine synthase, the enzyme that converts homocysteine into methionine. This reaction fuels the methylation cycle, the biochemical process supporting DNA synthesis, neurotransmitter production, and S-adenosylmethionine, the body's principal methyl donor.

B12 also operates in the mitochondrion, assisting methylmalonyl-CoA mutase in the metabolism of specific fatty acids and amino acids. This dual localization explains why a suboptimal B12 status manifests through hematological, neurological, and energy-related signals at once.

Reference Ranges

These reference ranges are derived from scientific literature and may differ from your laboratory's reference values.

Très faible< 23 pmol/L
Faible23 – 35 pmol/L
Optimal35 – 128 pmol/L
Élevé128 – 200 pmol/L
Très élevé> 200 pmol/L

Source : Hooshmand B et al. / Neurology (CAIDE cohort) (2010)

Biological Significance

An holotranscobalamin value in the optimal zone reflects satisfactory B12 bioavailability across all tissues. The methylation cycle and cellular energy production have access to the cofactor they require.

Suboptimal values signal reduced availability before total B12 itself declines. This is what makes the marker valuable: it reveals insufficient intake or absorption earlier. The early signal concerns at-risk profiles in particular: vegan diets, individuals over 65, or those on metformin or proton pump inhibitors.

When holo-TC is low, homocysteine offers a complementary reading also measured by Singular: it rises in case of methylation impairment. In clinical settings, another marker, methylmalonic acid, may be used to explore the mitochondrial B12 pathway. Singular also measures vitamin B9, enabling an integrated reading of the methylation crossroads.

Very high holo-TC values typically reflect active oral supplementation. They do not pose an overload risk, as excess B12 is eliminated through the kidneys.

Influencing Factors

Diet. Vitamin B12 comes exclusively from animal sources: meat, fish, eggs, and dairy. Strict vegan diets rapidly lead to declining holo-TC without adapted supplementation. Long-term vegetarian diets also carry a risk of progressive decline.

Gastrointestinal absorption. B12 absorption depends on intrinsic factor, a protein secreted by the parietal cells of the stomach. Age-related gastric atrophy reduces this secretion. This explains why B12 status weakens beyond 65, even when dietary intake is adequate.

Medications. Some medications modulate B12 absorption or availability. Metformin, used in the context of glucose metabolism, interferes with ileal absorption of vitamin B12. The DPPOS cohort documented increased risk after several years of use. Proton pump inhibitors and antacids reduce the gastric acidity needed to release B12 from food.

Genetics. Polymorphisms in the TCN2 gene, which codes for transcobalamin II, modulate circulating holo-TC at equivalent intake. These variants do not alter the biological function of B12 but influence measured values.

Supplementation. Oral supplementation with methylcobalamin or cyanocobalamin rapidly raises holo-TC. Singular uses methylcobalamin, directly usable by methionine synthase without an enzymatic conversion step.

Age. B12 needs increase with age due to reduced absorption. Regular holo-TC measurement after 50 allows intake to be adjusted before functional signals such as elevated homocysteine appear.

Methylation cofactors. Vitamins B9 and B6, along with trimethylglycine, participate in the same biochemical cycle as B12. An imbalanced intake can mask or amplify the reading of B12 status, justifying an integrated approach to the methylation crossroads.

In the Singular Formula

The Singular formulation engine uses holo-TC as a central marker of functional vitamin B12 status. Several concrete rules adjust the formula based on the observed zone.

When holo-TC sits in the low zone, vitamin B12 is calibrated to a sustained dose to restore cellular availability. In the very low zone, the dose is reinforced further. Singular formulates with methylcobalamin, directly usable by methylation enzymes. When the marker returns to the optimal zone, the formula moves to a maintenance dose.

A specific safety logic frames vitamin B9. High folate intake can mask the hematological picture without changing actual B12 availability, blurring the reading of B12 status. When holo-TC is low, vitamin B9 dosing is deliberately moderated to avoid masking B12 dynamics.

The engine systematically cross-references holo-TC with two other markers of the methylation crossroads. When homocysteine is elevated and holo-TC remains low, vitamin B12 takes priority. When homocysteine is elevated but holo-TC is already optimal, the formula reinforces folates or methyl support instead. This cross-reading avoids generic corrections and targets the truly limiting link.

Beyond B12 itself, trimethylglycine and vitamin B6 in its P5P form are selected for their documented contribution to the methylation cycle. Iron, whose metabolism intersects with red blood cell formation, completes this integrated reading of hematological and energy status.

Scientific Studies

AuthorsYearTypeJournal

Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study

CAIDE cohort of 271 elderly Finnish subjects followed for 7 years. Higher baseline holotranscobalamin was associated with a more favorable cognitive trajectory, independent of other factors.

Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility

Analytical review of holotranscobalamin as an early marker of B12 status. The holo-TC fraction, about one quarter of circulating cobalamin, identifies insufficient intake more reliably than total B12.

Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B12 status in the elderly

Study of 700 elderly subjects aged 63 to 97. Holo-TC achieved the best discriminative performance (AUC 0.90) compared with total B12 (0.80) and methylmalonic acid (0.78), with fewer indeterminate observations.

Diagnostic Accuracy of Holotranscobalamin, Vitamin B12, Methylmalonic Acid, and Homocysteine in Detecting B12 Deficiency in a Large, Mixed Patient Population

Analysis of the four B12 markers in a large mixed population. Holo-TC achieved the highest AUC (0.92), particularly in women over 50.

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study

Thirteen-year follow-up of the DPPOS cohort. Individuals taking metformin showed low B12 in 19.1% at 5 years and 20.3% at 13 years, with a 13% increase per year of use.

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial

VITACOG randomized controlled trial on 271 subjects over 70. Supplementation with folate, B12, and B6 slowed brain atrophy by 30% on average and 53% in subjects with homocysteine above 13 µmol/L.

Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis

Meta-analysis of 25 studies comparing 2,852 PPI users with 28,070 non-users. The pooled odds ratio for low B12 status was 1.42, with dose and duration-dependent influence.

Frequently Asked Questions

The information on this page is provided for informational and educational purposes only. It does not constitute medical advice and is not a substitute for consultation with a healthcare professional.

Holo-TC: the active fraction of vitamin B12 explained | Singular